Campbell & CO Investment Adviser LLC Viking Therapeutics, Inc. Transaction History

Campbell & CO Investment Adviser LLC

  • $1.15 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
SELL
$17.4 - $94.5 $438,184 - $2.38 Million
-25,183 Reduced 86.01%
4,095 $335,000
Q4 2023

Feb 13, 2024
BUY
$9.24 - $19.64 $270,528 - $575,019
29,278 New
29,278 $544,000
Q2 2023

Aug 11, 2023
BUY
$14.84 - $24.79 $274,183 - $458,020
18,476 New
18,476 $299,000
Q1 2022

May 09, 2022
SELL
$3.0 - $4.88 $160,800 - $261,568
-53,600 Closed
0 $0
Q4 2021

Feb 10, 2022
BUY
$4.6 - $6.72 $246,559 - $360,192
53,600 New
53,600 $247,000

Others Institutions Holding VKTX

# of Institutions
442
Shares Held
63.3M
Call Options Held
6.23M
Put Options Held
2.97M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email